Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Eduard Brunet"'
Autor:
Francisco Mesonero, Yamile Zabana, Agnès Fernández-Clotet, Eduardo Leo-Carnerero, Berta Caballol, Andrea Núñez-Ortiz, María José García, Federico Bertoletti, Alejandro Mínguez, Gerard Suris, Begoña Casis, Rocío Ferreiro-Iglesias, Margalida Calafat, Itxaso Jiménez, José Miranda-Bautista, Luis Javier Lamuela, Ingrid Fajardo, Leyanira Torrealba, Rodrigo Nájera, Rosa María Sáiz-Chumillas, Irene González, Miren Vicuña, Natalia García-Morales, Ana Gutiérrez, Alicia López-García, José Manuel Benítez, Cristina Rubín de Célix, Coral Tejido, Eduard Brunet, Alejandro Hernández-Camba, Cristina Suárez, Iago Rodríguez-Lago, Marta Piqueras, Andrés Castaño, Laura Ramos, Ana Sobrino, María Carmen Rodríguez-Grau, Alfonso Elosua, Miguel Montoro, Ruth Baltar, José María Huguet, Benito Hermida, Antonio Caballero-Mateos, Luis Sánchez-Guillén, Abdel Bouhmidi, Ramón Pajares, Iria Baston-Rey, Antonio López-Sanromán, Agustin Albillos, Manuel Barreiro-de Acosta
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. Design: This was a
Externí odkaz:
https://doaj.org/article/ef3f5804828b4e3a9155f26cccf14c09
Autor:
Eduard Brunet-Mas, Belen Garcia-Sagué, Emli Vela, Luigi Melcarne, Laura Patricia Llovet, Caridad Pontes, Pilar García-Iglesias, Anna Puy, Sergio Lario, Maria Jose Ramirez-Lazaro, Albert Villoria, Johan Burisch, Gilaad G. Kaplan, Xavier Calvet
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs. Objectives: The aim of this study was to evaluate the current healthcare expenditure associated with IBD in a population-wide study in Catalonia. Design: Re
Externí odkaz:
https://doaj.org/article/b1f12d90310743588d3ef91ff92bfe9d
Autor:
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, Rubén Sánchez-Aldehuelo, Montserrat Rivero, Marisa Iborra, María González-Vivo, Isabel Vera, Luisa de Castro, Luis Bujanda, Manuel Barreiro-de Acosta, Carlos González-Muñoza, Xavier Calvet, José Manuel Benítez, Mónica Llorente-Barrio, Gerard Surís, Fiorella Cañete, Lara Arias-García, David Monfort, Andrés Castaño-García, Francisco Javier Garcia-Alonso, José M. Huguet, Ignacio Marín-Jímenez, Rufo Lorente, Albert Martín-Cardona, Juan Ángel Ferrer, Patricia Camo, Javier P. Gisbert, Ramón Pajares, Fernando Gomollón, Jesús Castro-Poceiro, Jair Morales-Alvarado, Jordina Llaó, Andrés Rodríguez, Cristina Rodríguez, Pablo Pérez-Galindo, Mercè Navarro, Nuria Jiménez-García, Marta Carrillo-Palau, Isabel Blázquez-Gómez, Eva Sesé, Pedro Almela, Patricia Ramírez de la Piscina, Carlos Taxonera, Iago Rodríguez-Lago, Lidia Cabrinety, Milagros Vela, Miguel Mínguez, Francisco Mesonero, María José García, Mariam Aguas, Lucía Márquez, Marisol Silva Porto, Juan R. Pineda, Koldo García-Etxebarría, Federico Bertoletti, Eduard Brunet, Míriam Mañosa, Eugeni Domènech
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a sec
Externí odkaz:
https://doaj.org/article/775611ead93843fdbf2cc167c6af141b
Autor:
Carme Loras, Pablo Ruiz-Ramirez, Juan Romero, Xavier Andújar, Josep Bargallo, Esther Bernardos, Marta Maia Boscá-Watts, Carlo Brugiotti, Eduard Brunet, David Busquets, Elena Cerrillo, Francisco Javier Cortina, Juan Antonio Díaz-Milanés, Carmen Dueñas, Ramón Farrés, Thomas Golda, Ferran González-Huix, Joan B. Gornals, Jordi Guardiola, David Julià, Alba Lira, Jordina Llaó, Miriam Mañosa, Ingrid Marin, Mónica Millán, David Monfort, David Moro, Josep Mullerat, Mercè Navarro, Francisco Pérez Roldán, Eva Pijoan, Vicente Pons, José Reyes, María Rufas, Empar Sainz, Vicente Sanchiz, Anna Serracant, Eva Sese, Cristina Soto, Jose Troya, Natividad Zaragoza, Cristian Tebé, Marta Paraira, Emma Sudrià-Lopez, Vicenç Mayor, Fernando Fernández-Bañares, Maria Esteve, on behalf of the Grupo Español de Trabajo de la Enfermedad de Crohn y Colitis Ulcerosa GETECCU
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background Stenosis is one of the most common complications in patients with Crohn’s disease (CD). Endoscopic balloon dilation (EBD) is the treatment of choice for a short stenosis adjacent to the anastomosis from previous surgery. Self-ex
Externí odkaz:
https://doaj.org/article/d9294899328c4f91bb06c604813f1fb3
Autor:
Eduard Brunet, Emili Vela, Luigi Melcarne, Laura-Patricia Llovet, Anna Puy, Montserrat Clèries, Caridad Pontes, Pilar García-Iglesias, Albert Villòria, Gilaad G. Kaplan, Xavier Calvet
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 1255-1264 (2022)
Background Heterogeneity in the treatment of a disease is a marker of suboptimal quality of care. The aim of this study is to evaluate the heterogeneity in the treatment used and the outcomes for Crohn’s disease (CD) in Catalonia.Methods All patien
Externí odkaz:
https://doaj.org/article/9424724bafa44d5c883287f895b65a1a
Autor:
Gerard Grau, Eduard Brunet-Mas, Laura Patricia Llovet, Patricia Pedregal, Albert Villoria, Luigi Melcarne, Anna Puy, Belen Garcia-Sague, Luis Enrique Frisancho, María José Ramírez-Lázaro, Sergio Lario, Xavier Calvet
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 20, p 6571 (2023)
Background and objectives: Thiopurines are an effective treatment for the maintenance of remission in inflammatory bowel disease (IBD). They can present adverse effects (AEs), with myelotoxicity being the most relevant. This study aims to determine t
Externí odkaz:
https://doaj.org/article/f6928a317d9e49babb7d3157c5cd1a84
Autor:
Eduard Brunet Mas, Xavier Calvet Calvo
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 4, p 1076 (2022)
Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100% response rates, and a subset of refractory and severely ill patients have persistent active disease after being treated with all possible drug alternatives. The comb
Externí odkaz:
https://doaj.org/article/809b9cb22b7f4e188d5978e65ed02f73
Autor:
Eduard Brunet, Emili Vela, Luigi Melcarne, Montserrat Clèries, Caridad Pontes, Laura Patricia Llovet, Pilar García-Iglesias, Marta Gallach, Albert Villòria, Mercedes Vergara, Xavier Calvet
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 9, p 2896 (2020)
Background and Aims: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn’s disease (CD) by reducing the need for surgery or hospitalization. The aim of this study is to evaluate the time-trends of the use of bi
Externí odkaz:
https://doaj.org/article/30d7b9410c15459aa295bdb29bbc218e
Autor:
Jan Kral, Radislav Nakov, Vera Lanska, Brigida Barberio, Nicolas Benech, Andreas Blesl, Eduard Brunet, Tiago Capela, Lauranne Derikx, Gabriele Dragoni, Aileen Eek, Catarina Frias-Gomes, Georgiana-Emmanuela Gîlcă-Blanariu, Leah Gilroy, Philip Harvey, Anna Kagramanova, Haluk Kani, Tom Konikoff, Matthias Lessing, Gorm Madsen, Vaidota Maksimaityte, Maria Miasnikova, Ivana Mikolašević, Vladimir Milivojevic, Daniele Noviello, Dmytro Oliinyk, Arpad Patai, Anthea Pisani, Adonis Protopapas, Iago Rodríguez-Lago, Philipp Schreiner, Vita Skuja, Florian Tran, Marie Truyens, Marcin Włodarczyk, Hubert Zatorski, Bram Verstockt, Jonathan Philip Segal
Publikováno v:
Digestive Diseases, 41, 387-395
Digestive Diseases, 41, 3, pp. 387-395
Digestive Diseases, 41, 3, pp. 387-395
Item does not contain fulltext BACKGROUND: Inflammatory bowel disease (IBD) care and education might differ around Europe. Therefore, we conducted this European Variation In IBD PracticE suRvey (VIPER) to investigate potential differences between cou
Publikováno v:
Gastroenterología y Hepatología.